WO2008068923A1 - 核酸分解剤および核酸の分解方法 - Google Patents
核酸分解剤および核酸の分解方法 Download PDFInfo
- Publication number
- WO2008068923A1 WO2008068923A1 PCT/JP2007/064073 JP2007064073W WO2008068923A1 WO 2008068923 A1 WO2008068923 A1 WO 2008068923A1 JP 2007064073 W JP2007064073 W JP 2007064073W WO 2008068923 A1 WO2008068923 A1 WO 2008068923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- bacteria
- ema
- agent
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/26—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds containing nitrogen-to-nitrogen bonds, e.g. azides, diazo-amino compounds, diazonium compounds, hydrazine derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a nucleic acid degrading agent comprising ethidium monoazide (also referred to as ethidium monoazide) as an active ingredient, and ethidium monoazide to a sample containing cells. It is a method for degrading cellular nucleic acid, comprising a step of degrading intracellular nucleic acid by irradiating visible light to the sample.
- ethidium monoazide also referred to as ethidium monoazide
- Ethiji 1 nom monoant (3-ammo— 8— azido— 5— ethy ⁇ 6— pheny ⁇ pnenanthridmium chlon de) This is an azide compound with a modified chemistry medium (Non-patent Document 1).
- EMA is also known as a topoisomerase poison of eukaryotic cells (Non-patent Document 2), and as an agent such as probiotic musculare, a nuclear dye, Used! (Non-patent Document 3).
- Non-Patent Document 1 Nucleic Acids Res., 5th, 1978, 4891-4903
- Non-Patent Document 2 Biochemistry, Vol.36, No.50, 1997, pp. 1584-15891
- Non-Patent Document 3 Applied and Environmental Mental Microbiology (Appl. Env iron. Microbiol.), No. 71, No. 2, 2005, pp. 1018-1024
- An object of the present invention is to provide a nucleic acid degrading agent useful as an antibacterial agent such as a bactericidal or disinfecting agent.
- the inventors of the present invention have made extensive studies on antibacterial agents, particularly agents that kill bacteria. Nucleolytic agents that permeate the cell walls of bacteria and act directly on the nucleic acids of the bacteria to cleave the nucleic acids. As a result of searching for substances having such actions, it was found that EMA, which is an azide compound, has the effect of permeating the cell walls of live bacteria and cleaving nucleic acids. Was completed.
- a first invention of the present invention that solves the above-mentioned problems is a nucleic acid decomposing agent comprising ethidium monoazide as an active ingredient.
- a second invention of the present invention that solves the above problems is an antibacterial agent comprising the nucleic acid degrading agent of the first invention.
- a third invention of the present invention that solves the above-described problems includes a step of adding ethidium monoazide to a sample containing nucleic acid, and a step of decomposing nucleic acid in the sample by irradiating the sample containing the nucleic acid with visible light, This is a method for decomposing nucleic acid in a sample containing nucleic acid.
- a fourth invention of the present invention that solves the above problems includes a step of adding ethidium monoazide to a sample containing cells, and a step of irradiating the sample containing cells with visible light to degrade nucleic acids in the cells. This is a method for degrading intracellular nucleic acids.
- FIG. 1 is an electrophoretogram showing the effect of EMA in the in vitro mouth on Escherichia coli chromosomal DNA and rRNA.
- M represents a molecular weight marker (ZECOT14 I digest).
- IR (-) indicates no visible light irradiation, IR indicates visible light irradiation (500W halogen bulb, 20 minutes).
- the numerical value of E0-1 00 n or ⁇ represents the final concentration of EMA (0-100 ng / ml or ⁇ g / ml).
- FIG. 2 An electrophoretogram showing the effect of EMA on chromosomal DNA and rRNA in vivo.
- M represents a molecular weight marker (ZECOT14 I digest).
- IR (-) indicates no visible light irradiation, IR indicates visible light irradiation (500W halogen bulb, 20 minutes).
- the numerical value of E0-1 00 n or ⁇ represents the final concentration of EMA (0-100 ng / ml or ⁇ g / ml).
- FIG. 3 Antibacterial effect and dose response curve of EMA.
- the X-axis shows the final concentration of EMA (g / ml).
- the Y axis shows the decrease in the number of viable bacteria (CFU / ml) in each EMA-treated area with respect to the initial development by the common logarithm.
- FIG. 4 is a photograph showing the results of observation of E. coli DH5 a chromosomal DNA with EMA and visible light irradiation (500 W halogen bulb, 20 minutes) under an electron microscope.
- the final concentrations of EMA are (1) 0, (2) 0.0: g / ml, (3) 1
- the nucleic acid degrading agent of the present invention has an effect of directly acting on an isolated nucleic acid and degrading it at random, and is also an active ingredient for nucleic acid present in a sample containing nucleic acid. Permeates into the sample and acts directly, and has the effect of randomly cleaving those nucleic acids.
- the nucleic acid includes DNA and RNA.
- Nucleic acids targeted by the nucleic acid degrading agent of the present invention include single-stranded DNA, double-stranded DNA, single-stranded RNA, and double-stranded RNA.
- the sample to which the present invention is applied may contain two or more kinds which may contain any of these.
- Examples of the target of the nucleic acid degrading agent of the present invention include chromosomal DNA and plasmid DNA, and rRNA, mRNA, and tRNA.
- Samples containing nucleic acids include all biological cells, for example, prokaryotic cells (bacteria), eukaryotic cells, etc. (protists, fungi, plants, animals, etc.), viruses, etc., but bacteria, fungi, Viruses and the like are particularly preferable.
- prokaryotic cells bacteria
- eukaryotic cells etc.
- protists fungi, plants, animals, etc.
- viruses etc.
- bacteria, fungi, Viruses and the like are particularly preferable.
- the nucleic acid degrading agent of the present invention stops the growth of these bacteria, fungi, viruses, etc., and kills them by directly degrading intracellular nucleic acids. Has an effect. Therefore, for example, the nucleic acid degrading agent of the present invention is used as an antibacterial agent or disinfectant / disinfectant for environmental microorganisms, or an antiviral agent, etc. be able to.
- Environmental microorganisms targeted by the antibacterial agent of the present invention are not particularly limited, but examples include pacteria and fungi.
- Nocteria includes both gram-positive and gram-negative bacteria.
- Gram-positive bacteria include Staphylococcus spp., Streptococcus spp., Listeria spp., Bacillus spp., Mycobacterium spp., Clostridium spp., Such as Staphylococcus epidermidis Examples include bacteria.
- Gram-negative bacteria include Escherichia bacteria such as Escherichia coli, Enterobacteria group typified by Enterobacter bacteria, Salmonella bacteria, Vibrio bacteria, Syudomonas bacteria, Legionella bacteria And Campylobacter bacteria.
- the fungi targeted by the antibacterial agent of the present invention are not particularly limited, and examples thereof include Candida bacteria, Aspergillus bacteria, Saccharomyces bacteria, and Pecyllium bacteria.
- EMA 3-amino-8-azido-5-ethy ⁇ 6-phenyl-phenanthridinium chloride
- the amount of the nucleic acid decomposing agent of the present invention can be appropriately selected depending on whether the nucleic acid to be decomposed extracellularly or intracellularly is degraded, and depending on the amount of the nucleic acid to be degraded.
- the amount of EMA contained in the nucleic acid degrading agent at the time of use is 1 ⁇ g / ml to: L000 ⁇ g / m 1, preferably 10 ⁇ g / ml to: L000 ⁇ g / ml, particularly preferably 100 ⁇ g / ml to: L000 ⁇ g Zml concentration. Nucleic acid can be effectively degraded by allowing such a concentration of the nucleic acid degrading agent to act on the target.
- nucleic acid degrading agent of the present invention can be used in a liquid or EMA itself. It may be appropriately diluted and dissolved occasionally.
- the nucleic acid degrading agent of the present invention can also be used as an antibacterial agent.
- the nucleic acid decomposing agent of the present invention is used as an antibacterial agent, it is the same as the nucleic acid decomposing agent.
- visible light When decomposing nucleic acids, visible light is irradiated.
- the wavelength of visible light to be irradiated is 380 nm to 800 nm, preferably 450 nm to 600 nm.
- the visible light may be a single wavelength or a mixed light distributed in the above range. Further, it may contain light having a wavelength outside the above range.
- the light source power and the distance to the sample can be appropriately selected as long as a sufficient amount of irradiation can be performed on the target sample.
- visible light can also be irradiated by placing the target of the nucleic acid decomposing agent or antibacterial agent of the present invention under irradiation of natural light such as sunlight.
- nucleic acid degradation agent of the present invention for example, 0.5 5: when irradiated with light intensity of LOOWZcm 2, 5 minutes to 1 hour, preferably about sufficiently nuclease effect in about 5 to 30 minutes Can be demonstrated.
- the irradiation time is about 5 minutes to 1 hour, preferably 5 to 30 minutes, and the nucleic acid degradation effect can be sufficiently exerted.
- the effect of the nucleic acid decomposing agent of the present invention can be evaluated by electrophoresis of nucleic acids before and after the addition of the nucleic acid decomposing agent and the visible light irradiation treatment, and comparing them.
- it when applied to bacteria, it can also be indirectly evaluated by measuring the number of viable bacteria.
- the nucleic acid degrading agent of the present invention may be used alone or in combination with other components.
- other components include known nucleolytic agents, such as endonucleases such as exonuclease and restriction enzymes for DNA and RNA, and the combined use with these can further enhance the nucleolytic effect. .
- the usage form of the antibacterial agent of the present invention is not particularly limited. For example, it may be added to the solution and used, or an appropriately diluted solution may be sprayed.
- the dosage form of the antibacterial agent of the present invention can be appropriately selected according to the use, usage form, and the like, and is not particularly limited, and examples thereof include liquids, granules, tablets and the like.
- the antibacterial agent of the present invention may be used alone or in combination with other components.
- antibacterial agents and fungicides such as antibiotics, alcohols such as ethanol and isopropyl alcohol, phenol and cresol, halogen compounds (chlorine, iodine, etc.) and peroxides (ozone, ozone, etc.).
- halogen compounds chlorine, iodine, etc.
- peroxides ozone, ozone, etc.
- oxidants such as hydrogen peroxide
- heavy metal compounds and the like
- the antibacterial agent of the present invention can be suitably used, for example, for disinfection of instruments and the like and disinfection of wall surfaces and floor surfaces.
- by spraying the antibacterial agent of the present invention in indoor spaces it is possible to sterilize bacteria (pathogenic Escherichia coli, tuberculosis bacteria, Clostridium botulinum, Bacillus anthracis, etc.) that are highly likely to become serious when infected to humans. Very useful.
- the antibacterial agent of the present invention can be directly degraded by acting on nucleic acids in cells, it is unnecessary to consider the problem of resistance in bacteria. Therefore, it has excellent antibacterial activity and has a broad antibacterial spectrum.
- the prepared nucleic acid solution was adjusted to 175 ng / ⁇ 1 with sterile water, and this nucleic acid solution was collected in a microtube for 4 minutes, and each of the above EMA aqueous solutions (0, 0.02, 0. 2, 2, 20, 200 gZml) was added to the plate and left at 4 ° C for 1 hour in the dark. Thereafter, the sample was irradiated with visible light from a 500 W halogen bulb (FLOOD PRF 100V 500W; Iwasaki Electric, Tokyo) for 20 minutes at a distance of 2 Ocm from the sample, and the entire amount was electrophoresed on a 0.7% agarose gel.
- FLOOD PRF 100V 500W Iwasaki Electric, Tokyo
- E-EcoT14 I digest (Takara Bio Inc.) was used as a molecular weight marker.
- the gel after electrophoresis was stained with 1 ⁇ g Zml bromide solution, irradiated with UV 254 nm using a UV transilluminator, and the image was recorded on Polaroid film 667.
- a non-treated ( ⁇ : 0 / ⁇ 8 ⁇ 1, non-irradiated visible light) nucleic acid solution was used for electrophoretic movement in the same manner.
- Figure 1 shows the results of this test. As a result, it was confirmed that the band derived from chromosomal DNA around 19,329 bp gradually decreased from lOOngZml to 1 ⁇ gZml and disappeared remarkably at 10 ⁇ gZml. It became apparent that chromosomal DNA in nucleic acids isolated from fungi (E. coli) was degraded.
- Test method EMA was dissolved in sterilized water to prepare a 1000 ⁇ g ZmlEMA solution, which was aseptically filtered through a 0.2 ⁇ m filter (Minisart-plus; manufactured by Sartorius AG). Using this EMA solution, the final concentration force of EMA SO (unattached caro) for 1.0 ml of live suspension of E. coli / DH5 ⁇ strain of 1.0 X 10 6 CFU / ml .01, 0.1, 1, 10, and 100 g / ml were added, and the mixture was allowed to stand at 4 ° C for 1 hour in the dark.
- EMA SO unattached caro
- the mixture was cooled and centrifuged at 15,000 Xg and 4 ° C for 10 minutes, the supernatant was removed, and 0.4 ml of 70% cold ethanol was added to wash the pellet (precipitate) (hereinafter referred to as “the pellet”).
- the above-mentioned series of operations may be abbreviated as “phenol Z black mouth form extraction”).
- 0.5 ml of 10 mM Tris-HCl buffer + lmM EDTA ′ 2Na solution (TE buffer 1) was added to the pellet, and the mixture was left overnight at 4 ° C. to dissolve the nucleic acid.
- Evaluate the concentration of the purified nucleic acid solution by UV260nm absorbance (nucleic acid 50 / z gZml OD l, cell length lcm: OD)
- the purity of the purified nucleic acid was evaluated by OD / OD.
- Each nucleic acid solution was prepared at 175 ng / ⁇ l, and 4 ⁇ l was electrophoresed on a 0.7% agarose gel.
- E-EcoT14 I digest (Takara Bio Inc.) was used as a molecular weight marker.
- the gel after electrophoresis was stained with a 1 ⁇ g / ml bromide solution, irradiated with UV 254 nm using a UV transilluminator, and the image was recorded on Polaroid Film 667.
- Con The trawl used was a nucleic acid extracted from an untreated E. coli suspension (EMA 0 ⁇ g / m without visible light irradiation).
- Figure 2 shows the results of this test. As a result, it was confirmed that the band derived from chromosomal DNA at around 19,329 bp gradually decreased at 10 ⁇ gZml, and disappeared markedly at 100 ⁇ gZml. It was revealed that the chromosomal DNA present in) was degraded.
- Ethidium monoazide was dissolved in sterilized water to prepare a 1000 ⁇ g ZmlEMA solution, which was sterile filtered through a 0.2 ⁇ m filter (Minisart-plus; manufactured by Sartorius AG). Using the EMA solution, 1. OX 10 6 CFU / ml of E. coli / DH5 a strain live cell suspension lml, EMA final concentration is 0 (not added), 0.01, After adding to 0.1, 1, 10, and 100 gZml, the mixture was allowed to stand at 4 ° C for 1 hour in the dark.
- EMA Ethidium monoazide
- the antimicrobial effect of EMA is shown in Figure 3 as a dose response curve.
- E MA was reacted with E. coli at a concentration of 10 / z gZml
- the number of viable bacteria was reduced to the order of 10 2 CFU / ml compared to the initial number of bacteria, and 100 g / ml
- the reaction is carried out at a concentration of 1, the number of viable bacteria can be reduced to the order of 10 5 CFUZml compared to the number of first viable bacteria. It was confirmed.
- the nucleic acid was dissolved in 9 ml of sterilized water. Gently load the prepared nucleic acid solution onto the top of a 32 ml sucrose density gradient (using 16 ml of 10% sucrose solution and 16 ml of 40% sucrose solution), and swing rotor (Hitachi Koki Co., Ltd .: RPS-2 7-2) was used for ultracentrifugation treatment at 20 ° C and 26, OOOrpm for 18 hours. After centrifugation, a hole was made in the bottom of the sucrose density gradient solution, and 1 ml was fractionated.
- Figure 4 shows the results of this test.
- Fig. 4 shows the results of observation of E. coli chromosomal DNA under an electron microscope after EMA was applied at a concentration of 0 to 1 O / z gZml and irradiated with visible light (500 W halogen bulb, 20 minutes).
- visible light 500 W halogen bulb, 20 minutes.
- the nucleic acid degrading agent of the present invention has the property of permeating the cell walls of living bacteria and can cleave the chromosomal DNA and RNA of the bacteria at random, bacteriology and living In the chemical field, it is extremely useful as an antibacterial agent against environmental microorganisms, especially as a disinfectant. Further, the nucleic acid degrading agent of the present invention can be suitably used in the research field.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07790835A EP2090169A4 (en) | 2006-12-04 | 2007-07-17 | NUCLEIC ACID-DEGRADING AGENT AND METHOD OF REMOVING NUCLEIC ACID |
US12/092,677 US20100170777A1 (en) | 2006-12-04 | 2007-07-17 | Agent for degrading a nucleic acid and method of degrading a nucleic acid |
CA2633591A CA2633591C (en) | 2006-12-04 | 2007-07-17 | Agent for degrading a nucleic acid and method of degrading a nucleic acid |
AU2007302638A AU2007302638B2 (en) | 2006-12-04 | 2007-07-17 | Agent for degrading a nucleic acid and method of degrading a nucleic acid |
CN2007800044563A CN101378657B (zh) | 2006-12-04 | 2007-07-17 | 核酸降解剂和核酸的降解方法 |
NO20082129A NO20082129L (no) | 2006-12-04 | 2008-05-07 | Middel til nedbrytning av nukleinsyrer samt fremgangsmate for nedbrytning av nukleinsyrer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006326825A JP4113556B2 (ja) | 2006-12-04 | 2006-12-04 | 核酸分解剤および核酸の分解方法 |
JP2006-326825 | 2006-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008068923A1 true WO2008068923A1 (ja) | 2008-06-12 |
Family
ID=39491837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/064073 WO2008068923A1 (ja) | 2006-12-04 | 2007-07-17 | 核酸分解剤および核酸の分解方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20100170777A1 (ja) |
EP (1) | EP2090169A4 (ja) |
JP (1) | JP4113556B2 (ja) |
KR (1) | KR101017811B1 (ja) |
CN (2) | CN101378657B (ja) |
AU (1) | AU2007302638B2 (ja) |
CA (1) | CA2633591C (ja) |
NO (1) | NO20082129L (ja) |
RU (1) | RU2388473C2 (ja) |
WO (1) | WO2008068923A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015053293A1 (ja) * | 2013-10-07 | 2015-04-16 | 三井化学株式会社 | 細菌dna増幅用のpcr用プライマーセット、細菌種の検出及び/または同定用キット及び細菌種の検出及び/または同定方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9458498B2 (en) | 2011-01-24 | 2016-10-04 | Takara Bio Inc. | Method for modifying nucleic acids |
CN108333350A (zh) * | 2017-12-19 | 2018-07-27 | 宝瑞源生物技术(北京)有限公司 | 免疫探针降解pcr层析核酸检测法 |
WO2020027133A1 (ja) * | 2018-07-30 | 2020-02-06 | 株式会社シーライブ | 滅菌・核酸分解用組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63313598A (ja) * | 1987-03-11 | 1988-12-21 | バイエル・コーポレーシヨン | 核酸含有試料中の核酸配列のアツセイ |
JP2003530118A (ja) * | 2000-04-10 | 2003-10-14 | マトフォルスク | 細胞検出方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695453A (en) * | 1985-01-24 | 1987-09-22 | Henkel Corporation | Thickened alcoholic antimicrobial compositions |
US5348855A (en) * | 1986-03-05 | 1994-09-20 | Miles Inc. | Assay for nucleic acid sequences in an unpurified sample |
US6815172B1 (en) * | 1999-06-11 | 2004-11-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for opsonophagocytic assays |
CA2615984C (en) * | 2005-07-21 | 2013-04-23 | Morinaga Milk Industry Co., Ltd. | Method for detection of microorganism and kit for detection of microorganism |
-
2006
- 2006-12-04 JP JP2006326825A patent/JP4113556B2/ja active Active
-
2007
- 2007-07-17 WO PCT/JP2007/064073 patent/WO2008068923A1/ja active Application Filing
- 2007-07-17 RU RU2008124804/15A patent/RU2388473C2/ru not_active IP Right Cessation
- 2007-07-17 KR KR1020087011899A patent/KR101017811B1/ko not_active IP Right Cessation
- 2007-07-17 CN CN2007800044563A patent/CN101378657B/zh not_active Expired - Fee Related
- 2007-07-17 CN CN2011102245279A patent/CN102389577A/zh active Pending
- 2007-07-17 AU AU2007302638A patent/AU2007302638B2/en not_active Ceased
- 2007-07-17 US US12/092,677 patent/US20100170777A1/en not_active Abandoned
- 2007-07-17 CA CA2633591A patent/CA2633591C/en not_active Expired - Fee Related
- 2007-07-17 EP EP07790835A patent/EP2090169A4/en not_active Withdrawn
-
2008
- 2008-05-07 NO NO20082129A patent/NO20082129L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63313598A (ja) * | 1987-03-11 | 1988-12-21 | バイエル・コーポレーシヨン | 核酸含有試料中の核酸配列のアツセイ |
JP2003530118A (ja) * | 2000-04-10 | 2003-10-14 | マトフォルスク | 細胞検出方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015053293A1 (ja) * | 2013-10-07 | 2015-04-16 | 三井化学株式会社 | 細菌dna増幅用のpcr用プライマーセット、細菌種の検出及び/または同定用キット及び細菌種の検出及び/または同定方法 |
JPWO2015053293A1 (ja) * | 2013-10-07 | 2017-03-09 | 三井化学株式会社 | 細菌dna増幅用のpcr用プライマーセット、細菌種の検出及び/または同定用キット及び細菌種の検出及び/または同定方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2090169A4 (en) | 2010-02-10 |
EP2090169A1 (en) | 2009-08-19 |
NO20082129L (no) | 2008-08-28 |
RU2388473C2 (ru) | 2010-05-10 |
CA2633591C (en) | 2011-02-15 |
CN101378657A (zh) | 2009-03-04 |
JP2008137962A (ja) | 2008-06-19 |
CN102389577A (zh) | 2012-03-28 |
CA2633591A1 (en) | 2008-06-04 |
KR101017811B1 (ko) | 2011-02-28 |
AU2007302638A1 (en) | 2008-06-19 |
JP4113556B2 (ja) | 2008-07-09 |
KR20080088581A (ko) | 2008-10-02 |
US20100170777A1 (en) | 2010-07-08 |
RU2008124804A (ru) | 2009-12-27 |
AU2007302638B2 (en) | 2010-09-02 |
CN101378657B (zh) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ouyang et al. | Towards a better understanding of Pseudomonas putida biofilm formation in the presence of ZnO nanoparticles (NPs): Role of NP concentration | |
Chen et al. | Antibiotic-resistance gene transfer in antibiotic-resistance bacteria under different light irradiation: Implications from oxidative stress and gene expression | |
Hong et al. | Membrane lipid peroxidation in copper alloy-mediated contact killing of Escherichia coli | |
Dai et al. | Unraveling the anti-bacterial mechanism of Litsea cubeba essential oil against E. coli O157: H7 and its application in vegetable juices | |
Setlow | Spore resistance properties | |
Young et al. | Mechanisms of Bacillus subtilis spore resistance to and killing by aqueous ozone | |
Santo et al. | Bacterial killing by dry metallic copper surfaces | |
ES2908856T3 (es) | Método y sistema para lisis microbiana mediante el uso de peryodatos | |
Loshon et al. | Analysis of the killing of spores of Bacillus subtilis by a new disinfectant, Sterilox® | |
JP4918084B2 (ja) | タンパク質、核酸分子、および微生物の変性、修飾、分解、溶解、および除去のための除染液とその使用 | |
Leggett et al. | Resistance to and killing by the sporicidal microbicide peracetic acid | |
Bartoli et al. | Molecular mechanisms underlying the emergence of bacterial pathogens: an ecological perspective | |
WO2008068923A1 (ja) | 核酸分解剤および核酸の分解方法 | |
Li et al. | Killing the spores of Bacillus species by molecular iodine | |
Dong et al. | Killing of spores of Bacillus species by cetyltrimethylammonium bromide | |
Unterholzner et al. | Characterisation of the stbD/E toxin–antitoxin system of pEP36, a plasmid of the plant pathogen Erwinia pyrifoliae | |
Redondo et al. | Influence of selected bactericides on biofilm formation and viability of Xanthomonas citri subsp. citri | |
Mei et al. | Changes in gene transcription induced by hydrogen peroxide treatment of verotoxin-producing Escherichia coli O157: H7 and non-O157 serotypes on romaine lettuce | |
Martin et al. | Bacillus subtilis vegetative isolate surviving chlorine dioxide exposure: an elusive mechanism of resistance | |
Gonzales et al. | A high number of multidrug-resistant and predominant genetically related cluster of Shigella flexneri strains isolated over 34 years in Brazil | |
Ghosh et al. | Effects of the microbicide ceragenin CSA‐13 on and properties of Bacillus subtilis spores prepared on two very different media | |
WO2007061274A1 (fr) | Kit universel pour la lyse cellulaire | |
Huang et al. | LiaSR two-component system modulates the oxidative stress response in Streptococcus mutans | |
Fahmy et al. | Detection of Burkholderia cepacia in pharmaceutical products | |
Kovács et al. | Changes in the behavior of Staphylococcus aureus strains in the presence of oxacillin under the effect of gamma radiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2190/CHENP/2008 Country of ref document: IN Ref document number: 2007790835 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12092677 Country of ref document: US Ref document number: 567941 Country of ref document: NZ Ref document number: 2007302638 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2633591 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501137 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087011899 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008124804 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780004456.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07790835 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |